Pieris

AstraZeneca, Pieris collaborate for respiratory disease treatments

Wednesday, May 3, 2017

AstraZeneca announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals to develop novel inhaled drugs that leverage Pieris’ Anticalin platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering the potential of direct delivery to the lung.

[Read More]

Pieris, Servier partner on immuno-oncology

Friday, January 6, 2017

Pieris Pharmaceuticals, a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform, and Servier, an independent international pharmaceutical company, have announced a broad collaboration in immuno-oncology (IO). Despite the impressive clinical efficacy of checkpoint inhibitors to date, a majority of patients fail to respond to approved therapies. The collaboration seeks to address this significant unmet clinical need by advancing a series of novel molecules, including multiple dual immune checkpoint blockade approaches.

[Read More]

Pieris and Daiichi Sankyo partner to develop Anticalin therapeutics

Tuesday, April 12, 2011

Germany-based Pieris will collaborate with Japan-based Daiichi Sankyo and sign a licensed agreement under which Pieris will apply its Anticalin scaffold technology to discover novel Anticalins against two Daiichi Sankyo targets. As part of the agreement, Pieris will be responsible for early preclinical development for Anticalin drug candidates, and Daiichi Sankyo will assume responsibility for further development and marketing of the Anticalin compounds.

[Read More]